drugset / Trial / NCT02018419

Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients

NCT02018419

Phase 1/2 Withdrawn Mirror Biologics, Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This phase I/II study is designed to compare different treatment schedules of a personalized anti-cancer vaccine protocol which combines the cryoablation of a selected metastatic lesion with intra-tumor immunotherapy. The cryoablation causes the tumor to release tumor-specific antigens into the surrounding environment. The injection of bioengineered allogeneic immune cells, AlloStim(TM), into the lesion is designed to modulate the immune response and educate the immune system to kill other tumor cells.

Timeline

Start
2014-03
Primary completion
2014-03
Completion
2014-03

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject AlloStim Cell therapy Other

Indications